يعرض 1 - 10 نتائج من 123 نتيجة بحث عن '"personalized dosing"', وقت الاستعلام: 0.95s تنقيح النتائج
  1. 1
  2. 2
  3. 3
  4. 4
    دورية أكاديمية

    لا يتم عرض هذه النتيجة على الضيوف.

  5. 5
    دورية أكاديمية

    لا يتم عرض هذه النتيجة على الضيوف.

  6. 6
    دورية أكاديمية

    لا يتم عرض هذه النتيجة على الضيوف.

  7. 7
  8. 8
  9. 9
  10. 10

    المساهمون: Pulmonary medicine, AII - Cancer immunology, CCA - Cancer Treatment and quality of life, CCA - Cancer biology and immunology, Targeted Gynaecologic Oncology (TARGON), Damage and Repair in Cancer Development and Cancer Treatment (DARE), Guided Treatment in Optimal Selected Cancer Patients (GUTS), Groningen Research Institute for Asthma and COPD (GRIAC), Pharmaceutical Analysis, Critical care, Anesthesiology, Peri-operative and Emergency medicine (CAPE), Medicinal Chemistry and Bioanalysis (MCB), Biopharmaceuticals, Discovery, Design and Delivery (BDDD), Value, Affordability and Sustainability (VALUE), Real World Studies in PharmacoEpidemiology, -Genetics, -Economics and -Therapy (PEGET), Medical Oncology, Pulmonary Medicine

    المصدر: Frontiers in Oncology, 13:1136221. Frontiers Media S.A.
    Frontiers in Oncology, 13
    Frontiers in Oncology, 13:1136221. Frontiers Media SA
    Meertens, M, Muntinghe-Wagenaar, M B, Sikkema, B J, Lopez-Yurda, M, Retèl, V P, Paats, M S, ter Heine, R, Schuuring, E, Timens, W, Touw, D J, van Boven, J F M, de Langen, A J, Hashemi, S M S, Hendriks, L E L, Croes, S, van den Heuvel, M M, Dingemans, A-M C, Mathijssen, R H J, Smit, E F, Huitema, A D R, Steeghs, N & van der Wekken, A J 2023, ' Therapeutic drug monitoring guided dosing versus standard dosing of alectinib in advanced ALK positive non-small cell lung cancer patients : Study protocol for an international, multicenter phase IV randomized controlled trial (ADAPT ALEC) ', Frontiers in Oncology, vol. 13, 1136221 . https://doi.org/10.3389/fonc.2023.1136221

    وصف الملف: application/pdf